^(18)F-FDG PET/CT对B细胞淋巴瘤相关噬血细胞综合征患者的临床价值  

Clinical Value of ^(18)F-FDG PET/CT for Patients with B Cell Lymphoma-Associated Hemophagocytic Syndrome

作　　者：丁重阳[1] 刘红宇[2] 郭喆[1] 李洋洋[1] 杨文平[1] 李天女[1] 

机构地区：[1]南京医科大学第一附属医院核医学科,江苏南京210029 [2]浙江省台州市中心医院放射科,浙江台州318000

出　　处：《中国实验血液学杂志》2017年第1期133-137,共5页Journal of Experimental Hematology

摘　　要：目的:探讨^(18)F-FDG PET/CT在B细胞淋巴瘤相关噬血细胞综合征的临床应用价值。方法:回顾性分析23例确诊的B细胞淋巴瘤相关噬血细胞综合征患者的临床特点、实验室指标及^(18)F-FDG PET/CT显像资料。对pET参数与各实验室指标的相关性采用Spearman检验,对影响生存的不同因素采用Kaplan-Meier法分析。结果:23例患者于化疗前均行^(18)F-FDG PET/CT检查,脾脏的^(18)F-FDG摄取只与中性粒细胞计数及血红蛋白含量具有相关性(r=0.588,P=0.035;r=0.699,P=0.008),而骨髓的^(18)F-FDG摄取仅与中性粒细胞计数具有相关性(r=0.691,P=0.009);在所有的临床特点、实验室指标及^(18)F-FDGPET/CT检查参数中,只有PET参数是影响B细胞淋巴瘤相关噬血细胞综合征预后的不良因素。6例患者于化疗6周期后行第2次^(18)F-FDG PET/CT检查,化疗后PET/CT结果阴性患者5例,无1例死亡;化疗后PET/CT检测结果阳性患者1例,治疗无效死亡。结论:化疗前^(18)F-FDG PET/CT检测能够预测B细胞淋巴瘤相关噬血细胞综合征的预后,化疗后PET/CT检测结果阴性预示患者有较好的预后。Objective： To investigate the clinical value of 18F-FDG PET/CT for patients with B cell lymphoma-asso- ciated hemophagocytic syndrome. Methods： The clinical characteristics, laboratory parameters and 18F-FDG PET/CT data of 23 newly diagnosed patients sufferred from B cell lymphoma-associated hemophagocytic syndrome were retrospectively analyzed. The correlation between PET and laboratory parameters were determined using Spearman correlation test. The prognostic factors were analyzed by the Kaplan-Meier method. Results： 23 patients were all examined by 18F- FDG PET/CT before chemotherapy, the 18F-FDG uptake of spleen positively correlated with neutrophil count and hemoglobin content （ r = 0. 588, P = 0. 035 ; r = 0. 699, P = 0. 008 ）, respectively, and the 18F-FDG uptake of bone marrow positively correlated with neutrophil count only （r =0. 691, P =0.009）. Among all the clinical or laboratorial parameters and 18F-FDG PET/CT, only PET parameter was poor factor affecting prognosis of patients with B cell lymphoma-associated hemophagocytic syndrome. Out of 6 patients received PET/CT scans after 6 cycles of treatment, the 5 patients with negative PET/CT survived, and one patient with positive result died. Conclusion： Baseline 18 F-FDG PET/CT may provide prognostic information for the management of patients with B cell lymphoma-associated hemophagocytic syndrome, and the data of 18F-FDG PET/CT before chemotherapy may predict the pregnosis of the patients with negative resuits, and the negative PET/CT results after chemotherapy betokens a better prognosis of patients.

关 键 词：18F-FDG PET/CT B细胞淋巴瘤 噬血细胞综合征 

分 类 号：R733.1[医药卫生—肿瘤]